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IN1RODUCfiON: 
In 1971, Hepler and Frank reported that smoking marijuana 
significantly lowered the intraocular pressure (lOP) in nine of eleven 
healthy human subjects.l The fact that smoking marijuana de-
creased lOP was confirmed by subsequent experiments and reports 
soon surfaced suggesting marijuana use as a new treatment for glau-
coma.2,3 When scientific experiments are briefly summarized by the 
popular media, often times the information is incomplete and ac-
cepted uncritically. It is likely that this occurred with the studies 
done on cannabis and its derivatives in lowering lOP. An eyecare 
practitioner could easily be misinformed regarding the potential use 
of marijuana in treating glaucoma if the popular media and other 
secondary sources were his or her only reading. The purpose of this 
literature review is to critically summarize the research that has 
been done to determine the role, if any, cannabis derivatives may 
play in treating glaucoma. This is best accomplished by answering 
the following three questions: 
1) How effective are marijuana and its derivatives in lowering 
lOP when administered by different clinically relevant 
methods? 
2) What are the mechanisms of action of manJuana in lowering 
human lOP? 
3) What are the possible ocular and systemic side effects that 
accompany the use of cannabis? 
1 
MATERIALS AND METHODS: 
The reference literature for this review was obtained by 
runmng a MEDLINE File search via Paperchase™ using a Macintosh 
Plus™ computer, a Supra™ 2400 baud modem, and the Red Ryder™ 
(9.4) communications software. Search terms used were, "cannabis," 
"marijuana," and "tetrahydrocannabinol," all combined with 
"glaucoma," using the Boolean "AND" operator. Pertinent articles 
were also obtained from the reference sections of four established 
textbooks on ocular pharmacology.4,5,6,7 The MEDLINE citations were 
downloaded onto a floppy disk and the review was written using the 
Microsoft™ program WORD™ 4.0. The downloaded references file 
was opened as a separate window while creating this document. As 
references were cited in the text, they were "cut and pasted" from 
the reference window into the footnote window of the main text. 
2 
CLINICAL EFFECTIVENESS & SIDE EFFECTS: 
It has been estimated that to control ocular hypertension by 
smoking marijuana, daily inhalation of four cigarettes would be re-
quired. 8 In this regard it is of interest that adverse pulmonary ef-
fects have been observed in subjects who smoked three marijuana 
cigarettes per week. 8 Further, laboratory analysis of marijuana 
smoke has shown a toxic effect at least equivalent to tobacco smoke 
on the genetic activity of cultured lung cells.9 Finally, heavy mari-
juana smoking has also been shown to cause chronic bronchitis and 
metaplasia of the bronchial endothelium.IO These considerations il-
lustrate the risks of a treatment regimen consisting of marijuana in-
halation for the typical glaucoma patient. 
Thus, potential damage to the respiratory system that would 
probably accompany multiple marijuana cigarette smoking on a daily 
basis is one reason such a therapeutic regimen is unrealistic. 
However, it is not the only reason. Marijuana smoking is also ac-
companied by a variety of clinically undesirable physiological and 
psychological effects. Two well documented pharmacological effects 
of marijuana inhalation are a decrease in blood pressurell,l2 and 
tachycardia.l3, 14 In a study in which "marijuana naive" adults with 
primary open angle glaucoma (POAG) smoked a single marijuana ci-
garette, a 14% decrease in mean blood pressure was observed which 
required a minimum period of sixty minutes to return to the pre-
smoking level.l2 A study analyzing the pharmacologic effects of 
marijuana smoking in "healthy, experienced marijuana smokers" re-
vealed a 60% mean heart rate acceleration approximately twenty 
3 
minutes after smoking a single marijuana cigarette, with the pulse 
rate remaining above the pre-smoking level for an average of ninety 
minutes.14 
In an experiment m which glaucoma patients orally ingested 
the minimal dose of THC required to significantly lower their lOP's, 
the trials had to be prematurely discontinued due to "severe psycho-
logic and cardiac complications. "15 These complications were de-
scribed as "acute panic reactions, varying states of anxiety concern-
ing tachycardia and palpitations, depersonalization reactions, and 
paranoic tendencies." 15 These side effects would obviously discour-
age patient compliance with any drug therapy, especially in chronic 
disease conditions such as glaucoma. The psychological effects of 
daily marijuana smoking or THC ingestion would also place extensive 
restrictions on patient's normal daily activities, such as driving a 
car.8 
Recognizing the lOP lowering effects of smoking marijuana and 
considering its undesirable side effects, research efforts oriented 
toward identifying which constituent(s) of marijuana were respon-
sible for the observed lOP reduction. The ultimate goal of the re-
search was a preparation containing the lOP lowering component(s) 
of marijuana but lacking the side effects observed from smoking 
marijuana. 
In 1964, delta-9-tetrahydrocannabinol (THC) was identified as 
the major psychoactive component in marijuana.16 After the lOP 
lowering capabilities of marijuana were confirmed, experimentation 
proceeded to determine the lOP lowering effects of THC in human 
and animal subjects. Experiments were also performed to determine 
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the lOP lowering abilities of cannabinoids such as delta-8-THC, 11-
0H-delta-9-THC and related synthetic analogs. Rabbits were the 
subjects in the majority of these investigations. 
ORAL AND INTRAVENOUS THC: 
Studies in which encapsulated synthetic THC has been orally 
ingested in human subjects have shown lOP decreases similar in 
magnitude to that observed when marijuana is smoked.15' 17 
Intravenous THC administration in humans has also resulted in sub-
stantial lOP reductions.18 Systemic hypotension, tachycardia, and the 
psychological side effects that accompany marijuana smoking were 
also observed when THC was administered orally or intra-
venously .15,17, 18 
TOPICAL THC: 
The side effects which accompany marijuana inhalation, and 
oral and intravenous THC administration were not found when THC 
was administered as a topical ophthalmic preparation. Green con-
ducted an experiment in which THC was applied topically to rabbit 
eyes six times daily for a period of thirty days.19 Blood and urine 
samples from each animal were analyzed before the drug adminis-
tration began and again on day twenty nine. The subjects' general 
health along with specific ocular parameters were observed regu-
larly. On day thirty, all the rabbits were sacrificed and their ocular 
tissues were examined histologically. The authors concluded that, 
aside from eyelid irritation caused by the vehicle, there were "no 
important adverse effects of clinical significance caused by the con-
centrations of THC" used in the study .19 
5 
A double blind, randomized, controlled study usmg human vol-
unteers produced similar results with respect to ocular irritation.20 
THC was administered topically to each subject four times daily for a 
one week period. Of the initial twenty eight paid volunteers, five 
had to discontinue participation due to a burning sensation and/or 
lid swelling. However, those five subjects, four were in the control 
group, receiving the light mineral oil vehicle alone. No other ocular 
or systemic side effects were observed with any of the subjects in 
the treated group.20 
Animal studies gave encouraging results with respect to the 
lOP lowering abilities of THC and other cannabis derivatives. Green 
et al. reported a 25% mean lOP reduction in rabbits following intra-
venous administration of THC.21 Similar results were also reported 
by ElSohly et al. in a separate experiment.22 Green has also reported 
extremely high reductions in lOP when a high molecular weight hy-
drophillic fraction of cannabis was intravenously administered to 
rabbits.23 lOP reductions have also been reported in rabbits when 
various doses of delta-8-THC, 11-0H-delta-8-THC, and cannabinol 
have been intravenously administered.22 
In contrast, studies in which THC and other related compounds 
were administered topically as ophthalmic preparations to rabbits 
have produced conflicting reports. On the one hand, Green has re-
peatedly reported that topical THC significantly reduces lOP in rab-
bits.24,25 On the other hand, ElSohly has reported no significant lOP 
lowering effects from topical THC to rabbit eyes.22,26 When the 
studies by ElSohly are compared to the studies by Green, three maJor 
differences in experimental design become apparent. The first dif-
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ference is in the control groups used. ElSohly used the same group 
as controls throughout the experiment, whereas Green used the 
same rabbits as test animals one day and control animals the next. 
The neurological condition of some of the rabbits used in the two 
studies also differed. Normal adult rabbits were used in the two ex-
periments ElSohly performed.22,26 Green used normal adult rabbits 
and adult rabbits that had been subjected to unilateral supenor cer-
vical ganglionectomy.24,25 Green reported the observed lOP reduc-
tions in the eyes contralateral to the lesion as occurring in "normal" 
rabbit eyes. There were also differences in the number of subjects 
used in the studies by ElSohly and Green. ElSohly consistently used 
eight rabbits as subjects and eight rabbits as controls.22,26 In one 
study, Green reports mean percentage lOP reduction values as being 
derived from, "at least 6 eyes of 6 animals for each drug concentra-
tion."24 The experimental design of ElSohly is superior in determin-
ing the lOP lowering ability of topical THC because negative controls 
were used and a greater number of normal rabbits were used. In 
light of this negative evidence, Green's results do not appear con-
vmcmg. 
Green has also reported lOP reductions of 30% with topical 
administration of synthetic THC analogs in rabbit eyes.21 lOP de-
creases of up to 25% have also been reported by ElSohly following 
topical administration of other synthetic marijuana derivatives.26 
A widely cited Jamaican study reported that a water soluble 
extract of whole cannabis applied as a topical ophthalmic solution re-
duced mean lOP's in 23 glaucoma patients a minimum of 32.5% with 
no adverse side effects.27 Few who quote this study, however, note 
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that the frequency of administration was not given. Also, the exper-
imental protocol did not utilize a control group, and the solvent used 
to prepare this ophthalmic solution was not mentioned, nor used 
alone as a control. This alleged topically administered water soluble 
cannabis derivative has not been identified, despite diligent attempts 
by Green et ai.23,28 It is puzzling why this study was so frequently 
accepted in the literature, when the experimental design was so bla-
tantly poor. 
The side effects found to accompany marijuana smoking, and 
oral and intravenous THC administration indicated the need for a 
drug delivery method that bypassed the central nervous system. 
This consideration, along with the lOP reductions reported in rabbits 
with topical cannabinoid drops, inevitably led to topical THC trials 
with human subjects. Three controlled studies have been performed 
measuring lOP following topical administration of varying concen-
trations of THC in a light mineral oil vehicle. A previous report by 
Green determined light mineral oil to be the vehicle of choice for 
topical ocular application.29 Green found that light mineral oil 
showed no corneal toxicity and delivered the largest quantity of THC 
across the rabbit cornea, when compared to heavy mineral oil, 
sesame oil, and a glycol oleate.29 
One study using 0.05% and 0.10% topical THC solutions 
administered to six subjects with POAG found no significant effect on 
IOP, heart rate or blood pressure resulting from the drug administra-
tion.30 Another study in which normal subjects were administered a 
single drop of 1% topical THC (10-20 times the concentration of the 
previous study), likewise reported no effect on IOP.3 1 In yet a third 
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study, involving 23 normal subjects rece1vmg 1% topical THC four 
times daily for one week, no significant effect on lOP, blood pressure, 
pulse rate or respiratory rate was found.20 Thus, present evidence 
indicates that topical THC is ineffective in lowering lOP in humans. 
9 
PHARMACOLOGY: 
Experimental results from both human and animal studies have 
led to a great deal of uncertainty regarding the mechanism of action 
of marijuana and/or THC in lowering lOP in man. In a 1980 article, 
Green and Roth32 hypothesized that the lOP fall observed in rabbits 
after intravenous THC administration is "primarily" due to an in-
creased facility of aqueous outflow. This hypothesis was based on a 
study they performed in 1973 on anesthetized rabbits and in vitro 
rabbit uveal tissues.33 In the same article, the authors note that 
other animal studies have also shown a decrease in aqueous forma-
tion, a central nervous system effect, and alpha and beta adrenergic 
effects in the eye following THC administration.32 
In a 1982 study by Green et al.34, THC was intravenously ad-
ministered to rabbits and rhesus monkeys. The study found that in-
travenous THC lowered rabbit lOP's but had no lOP lowering effects 
in rhesus monkeys. From these results Green et al. concluded that, 
"species differences exist in the ocular responses to cannabinoids and 
that extrapolation of rabbit data to primate must be experimentally 
verified. "34 This statement illustrates the substantial need for fur-
ther experimentation to determine the site(s) and mechanism(s) of 
action by which THC lowers human lOP. Extrapolating from rabbit 
studies is insufficient. 
Crawford and Merritt have suggested a centrally mediated 
mechanism of action to explain the lOP reductions seen following 
marijuana inhalation. Their hypothesis is based on their experimen-
tal observations in studies using human subjects. Heart rate, lOP, 
and blood pressure were all measured at regular intervals following 
10 
the smoking of a single marijuana cigarette by a group of POAG pa-
tients. After the measured parameters had returned to pre-smoking 
levels, the time courses of each variable were plotted and compared. 
It was found that the changes in mean arterial pressure paralleled 
the changes in IOP.12 The author's concluded from this observation 
that the decrease in systemic blood pressure leads to decreased 
capillary pressure at the ciliary body which results in a decrease m 
aqueous humor production.I2 In support of their hypothesis, the 
author's cite a study in which lOP was measured in patients follow-
ing oral administration of either propanolol or atenoloi.35 This study 
also found that the maximal lOP reductions occurred simultaneously 
with the maximal systolic blood pressure reductions.35 
It is well accepted that the ultrafiltration component of aque-
ous production is dependent on the pressure gradient at the capillar-
ies of the ciliary body _36 Thus, it logically follows that a decrease in 
blood pressure at the ciliary processes would result in a decrease m 
the ultrafiltration component of aqueous production. If the 
Crawford/Merritt hypothesis regarding the mechanism by which 
marijuana lowers lOP is correct, then there is a significant limit to 
the amount of lOP lowering marijuana could induce. There is also 
secretory component to aqueous production that is not influenced by 
capillary pressure at the ciliary body.36 
The aforementioned centrally mediated mechanism of action 
proposed by Crawford and Merritt probably accounts for at least a 
partial amount of the observed lOP reduction accompanying mari-
juana use. It would be premature however to conclude from the 
1 1 
available evidence how much of the lOP reduction is due to the sys-
temic hypotension induced by THC administration. 
Benowitz et al. have reported that pretreatment with both at-
ropine and propranolol is required to completely inhibit the cardio-
vascular effects of intravenous THC.37 This indicates that THC acts on 
both divisions of the autonomic nervous system. The eye is inner-
vated by both divisions of the autonomic nervous system.38 Drugs 
presently prescribed to lower lOP's in glaucoma patients include a 
parasympathomimetic (Pilocarpine), a sympathomimetic 
(Epinephrine) and its pro-drug (Dipivefrin), and a group of Beta 
adrenergic antagonists (Timolol, Betaxolol, and Levobunolo1).38 These 
drugs are all administered as ophthalmic drops and exert their ef-
fects via a local mechanism of action on specific ocular tissues. The 
observation that THC exhibits autonomic activity on the cardiovascu-
lar system makes it probable that such activity occurs in the eye as 
well. 
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DISCUSSION: 
I believe that (a) the potential pulmonary health hazards, (b) 
the documented clinically unacceptable physiological effects, and (c) 
the unpredictable impairment of mental functioning that accompany 
marijuana smoking, preclude such therapy for the routine treatment 
of glaucoma. The three aforementioned considerations continually 
present themselves in the literature and are the apparent reasons 
that marijuana inhalation has been disregarded in the scientific lit-
erature as a means of stabilizing lOP in typical glaucoma patients. 
A substantial amount of further research is required to under-
stand the means by which marijuana lowers lOP in humans. The 
presence of a local effect on ocular structures must first be clearly 
demonstrated and at least partially understood before a topical glau-
coma medication can be developed from cannabis. The currently ac-
cepted centrally mediated lOP reduction secondary to systemic hy-
potension argues against the development of a locally acting glau-
coma medication from cannabis. 
Nineteen years ago, Hepler and Frank reported that marijuana 
smoking lowered the lOP in human subjects. The failure thus far to 
develop a preparation of cannabis that is capable of lowering lOP 
with minimal side effects, I feel, diminishes the possibility of a fu-
ture role for marijuana in routine glaucoma treatment. Further, the 
recent development of effective, topical preparations such as timolol, 
betaxolol and levobunolol, that possess minimal side effects in most 
people and have been wide I y accepted by the medical community, 3 9 
decrease the need for a cannabis preparation. In addition, it has 
1 3 
been noted that since cannabinoids are naturally occurring sub-
stances, they are unpatentable4 0 and thus unattractive to pharma-
ceutical compames wishing a return on the large research and devel-
opment expenses that would be required to develop F.D.A. approved 
medicinal derivatives from marijuana. 
A final point is that, although marijuana has been shown to 
lower lOP, there have not been any studies determining whether or 
not visual function is preserved following marijuana induced lOP re-
ductions. 
14 
CONCLUSIONS: 
1) Marijuana smoking, oral, and intravenous THC 
administration all exhibit lOP lowering effects in rabbits and 
human beings. 
2) THC prepared as a topical ophthalmic solution in mineral oil 
does not lower lOP in normal rabbits or in human beings. 
3) A cannabis preparation that exhibits lOP lowering abilities 
and is free of clinically undesirable side effects has not been 
developed. 
4) The site(s) and mechanism(s) of pharmacological action of 
THC in lowering lOP is not presently known. 
5) The development of Timolol, Betaxolol, and Levobunolol in 
the 1980's has provided eyecare practitioners with additional 
safe, effective, topical glaucoma medications, and substantially 
reduced the need for a cannabis preparation. 
1 5 
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